A massive analysis of UK Biobank data published this month links higher blood levels of branched-chain amino acids to a measurably lower risk of developing Parkinson’s disease, with the clearest signal showing up years before diagnosis.
The study, led by Zhiqing Chen and colleagues and published November 7 in npj Parkinson’s Disease, tracked 374,751 participants who were free of neurodegenerative disease at baseline. During follow-up, 2,838 people developed Parkinson’s. After adjusting for demographics, lifestyle, genetics, and metabolic health, those with moderately elevated total BCAA levels had a 12% lower risk, while those with the highest levels saw a 17% reduction compared to the low-level group, Parkinson’s News Today reported.
The prediagnostic window
What makes this prospective cohort study unusual is the timeline. Baseline BCAA levels were lower among participants whose blood was drawn closer to their eventual Parkinson’s diagnosis — a difference that became detectable roughly five to seven years before clinical onset. The researchers used LOESS smoothing to model these pseudotemporal patterns, effectively showing that BCAA metabolism shifts during the long preclinical phase of the disease.
“These findings suggest that altered BCAA metabolism may represent a prediagnostic metabolic feature of [Parkinson’s disease] and support further investigation of its biological and translational relevance,” the authors wrote in the paper.

Beyond risk ratios: brain structure and aging biomarkers
The team didn’t stop at incidence numbers. Higher circulating BCAAs — particularly leucine and valine — also correlated with healthier diffusion MRI white-matter microstructure, lower plasma neurofilament light chain (a marker of axonal injury), lower glial fibrillary acidic protein (a marker of astrocyte activation), and slower PhenoAge acceleration, a composite measure of biological aging.
The study linked higher BCAA levels to lower PhenoAge acceleration, suggesting the metabolic signature may reflect a slower biological aging process rather than a Parkinson’s-specific pathway alone.
What the numbers actually say
| Metric | Comparison | Adjusted Risk Reduction |
|---|---|---|
| Total BCAAs (moderate) | vs. low levels | 12% |
| Total BCAAs (high) | vs. low levels | 17% |
| Leucine (highest) | vs. lowest | 13% |
| Valine (moderate) | vs. low | 10% |
| Valine (high) | vs. low | 17% |
The protective associations were statistically significant in adults aged 60 and older, with hints in women and people with lower polygenic risk scores, though formal interaction tests did not confirm effect modification by age, sex, or genetic risk.
Unadjusted baseline BCAA levels were actually slightly higher in future cases — driven by the fact that those who developed Parkinson’s were older (median age 64 vs. 58) and more often male (63.2% vs. 45.9%) — a reminder of why multivariable adjustment matters.
Association, not prescription
The authors are careful: this is an observational study with a single baseline blood draw, so it cannot track within-person BCAA trajectories or establish causality. Reverse causation — early disease pathology lowering BCAA levels years before diagnosis — remains a plausible explanation for the prediagnostic dip. The paper explicitly states that clinical intervention studies would be required to determine whether modifying BCAA intake or metabolism could be beneficial.
Branched-chain amino acids — leucine, isoleucine, and valine — are essential nutrients obtained from protein-rich foods. They play roles in protein synthesis, energy metabolism, and neuronal signaling. Previous studies had reported altered BCAA levels in established Parkinson’s, but the direction of causality was muddy. This study, published November 7, is the largest to date to anchor those changes in a prediagnostic window using multimodal biomarkers.
The question now is whether the metabolic shift is a driver of resilience or a passenger of slower aging — and whether the five-to-seven-year window offers a viable target for intervention.